$ 130 / 10mg
999 in stock (can be backordered)
Thymosin Alpha-1 (TA1) is a 28-amino-acid peptide originally isolated from thymic tissue by Allan Goldstein at George Washington University. It is one of the most clinically studied immune-modulating peptides worldwide, with research spanning viral infections, autoimmune conditions, cancer immunology, and vaccine-response enhancement. Thymosin Alpha-1 peptide acts as a biological response modifier — priming and modulating the immune system rather than directly killing pathogens.
Thymosin Alpha-1 peptide activates toll-like receptors (TLR2, TLR9) on dendritic cells and macrophages, promoting antigen presentation and T-cell priming. It enhances T-cell maturation from thymocyte precursors, increases natural killer (NK) cell activity, and modulates the Th1/Th2 cytokine balance toward Th1-dominant cellular immunity. This broad immunomodulatory profile — enhancing immune surveillance while maintaining balance — distinguishes it from single-pathway immune stimulants.
Thymalin targets thymic restoration through bioregulatory peptide mechanisms. LL-37 provides innate-immunity and antimicrobial defense research. Selank bridges immune modulation with anxiolytic nootropic pathways through its tuftsin-based design.
Each 10 mg lyophilized vial contains Thymosin Alpha-1 peptide manufactured in the USA under sterile conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
Lyophilized Thymosin Alpha-1 peptide should be stored at -20°C in a sealed container protected from light and moisture for long-term stability. For reconstitution, use bacteriostatic water and gently swirl the vial until the powder is fully dissolved — never shake. Once reconstituted, store at 2–8°C (standard laboratory refrigeration) and use within 28 days. As a 28-amino-acid peptide, Thymosin Alpha-1 should be handled with care to preserve structural integrity; researchers are advised to prepare aliquots to minimize freeze-thaw cycles. Always use sterile technique when withdrawing from reconstituted vials. For research use only.
Thymosin Alpha-1 was first isolated and characterized in 1977 by Allan Goldstein and colleagues at George Washington University from calf thymus tissue (Thymosin Fraction 5). This discovery was part of a broader effort to identify the immunoactive components of the thymus gland, following decades of research into thymic function by pioneers including Jacques Miller at the Walter and Eliza Hall Institute. Thymosin Alpha-1 has since been the subject of over 500 peer-reviewed publications in PubMed, spanning immunology, virology, and oncology research. It has been studied in over 30 countries, with major research contributions from the National Cancer Institute, the University of Rome, and various institutions across Asia where it has been extensively investigated as an immune modulator. Thymosin Alpha-1 remains a benchmark compound in adaptive immunity and immune-reconstitution research. All referenced work pertains to preclinical and laboratory research settings.
AgeFix Thymosin Alpha-1 is verified to ≥99% purity by HPLC analysis and undergoes endotoxin screening to confirm levels below 0.1 EU/mg. Each 10 mg lyophilized vial is manufactured in the USA under sterile conditions, with a Certificate of Analysis (COA) available upon request.
Thymosin Alpha-1 acts as a biological response modifier that primes the immune system through toll-like receptor activation (TLR2, TLR9) rather than directly targeting pathogens. It modulates the Th1/Th2 cytokine balance and enhances T-cell maturation, making it uniquely suited for research on adaptive immune reconstitution in laboratory models.
Lyophilized Thymosin Alpha-1 should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. This product is intended for laboratory research use only and is not for human consumption.
